Intravascular lithotripsy

Intravascular lithotripsy (IVL) helps interventional cardiologists break down heavily calcified plaques in the coronary and peripheral arteries prior to percutaneous coronary intervention. Shockwave Medical, now a part of Johnson & Johnson MedTech, got the ball rolling with its IVL therapies that use shockwave pulses to clear out the calcified plaques. Several other companies have now entered the space, working to develop their own IVL systems that can improve patient outcomes.

Medical device company raises $36M for emitter-free IVL platform
Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.
Experts in interventional cardiology, medical billing unite to discuss Shockwave Medical’s IVL technology
Intravascular lithotripsy has quickly emerged as one of healthcare’s most in-demand technologies. Now Shockwave Medical, part of Johnson & Johnson MedTech, is co-hosting a webinar designed to teach coding and billing specialists how to code appropriately for peripheral and coronary IVL procedures.
Boston Scientific enters IVL arms race with acquisition worth up to $664M
Boston Scientific has agreed to acquire Bolt Medical, a California-based medical device company focused on developing new intravascular lithotripsy technologies. The news comes less than one year after Johnson & Johnson acquired IVL pioneers Shockwave Medical for $13 billion.
Intravascular lithotripsy technology now a top priority for many healthcare companies
After the significant success of Shockwave Medical's IVL therapy to break up heavily calcified vessels without trauma, there are now several companies working on their own IVL devices.
Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules
Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

Medical device company raises $36M for emitter-free IVL platform

Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.

The use of intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) is still safe and effective when patients present with calcified nodules (CNs), according to new long-term data published in EuroIntervention.[1] Researchers compared outcomes from patients with and without CNs, highlighting key similarities in stent expansion and luminal gain.

Experts in interventional cardiology, medical billing unite to discuss Shockwave Medical’s IVL technology

Intravascular lithotripsy has quickly emerged as one of healthcare’s most in-demand technologies. Now Shockwave Medical, part of Johnson & Johnson MedTech, is co-hosting a webinar designed to teach coding and billing specialists how to code appropriately for peripheral and coronary IVL procedures.

healthcare value value-based care money dollar

Boston Scientific enters IVL arms race with acquisition worth up to $664M

Boston Scientific has agreed to acquire Bolt Medical, a California-based medical device company focused on developing new intravascular lithotripsy technologies. The news comes less than one year after Johnson & Johnson acquired IVL pioneers Shockwave Medical for $13 billion.

Philips Healthcare's combined IVL and laser atherectomy catheter that is being used in the THOR trial to treat heavily calcified peripheral artery lesions.

Intravascular lithotripsy technology now a top priority for many healthcare companies

After the significant success of Shockwave Medical's IVL therapy to break up heavily calcified vessels without trauma, there are now several companies working on their own IVL devices.

Shockwave Medical’s IVL technology still safe, effective in patients with calcified nodules

Intravascular lithotripsy is still a safe and effective frontline preparation tool when PCI patients present with calcified nodules, a new two-year study confirmed. Researchers focused on stent expansion and luminal gain, among other key data points.

Video interview with J.D. Corl, MD, explaining the use of the new E8 and Javelin Shockwave IVL catheters in PAD.

New balloonless IVL catheter offers an alternative to atherectomy in tight lesions, CTOs

J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade.

Shockwave Javelin Peripheral IVL Catheter

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.

The Shockwave Medical M5+ new peripheral intravascular lithotripsy (IVL) catheter cuts procedures times in half and was showed for the first time at the American College of Cardiology (ACC) 2022 meeting. It is designed to break up calcium in heavily calcified arteries to avoid the need for vessel trauma caused by high pressure angioplasty.

IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Patient outcomes for these two treatments are similar, but choosing IVL may help improve clinical workflows.